Pediatric Drugs

Journal Title：Pediatric Drugs

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes:

-overviews of contentious or emerging issues.

-comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development.

-practical reviews covering optimum drug management of specific clinical situations.

-systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

-Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population.

-original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

Pediatric Drugs 为对儿科药物治疗（包括疫苗）感兴趣的医疗保健专业人员促进药物治疗各个方面的优化和进步。审查和原创研究文章计划为医疗保健决策者提供有关新生儿学所有领域药物治疗以及儿童和青少年护理问题的临床适用知识。该杂志包括：

- 有争议或新出现的问题的概述。

- 对与儿科发展各个阶段的药物治疗的有效和安全管理相关的主题进行全面的叙述性评论。

-涵盖特定临床情况的最佳药物管理的实用评论。

- 使用 PRISMA 声明中概述的明确、系统的方法，整理经验证据以回答特定研究问题的系统评价。

-Adis 药物审查新药和成熟药物在儿科人群中的治疗特性和位置。

- 原创研究文章报告精心设计的研究结果，与临床实践密切相关，例如临床药效学和药代动力学研究、临床试验、荟萃分析、结果研究以及药物经济学和药物流行病学研究。

其他数字功能（包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画）可以与文章一起发布；这些旨在提高期刊内容的知名度、读者群和教育价值。此外，Pediatric Drugs 上发表的文章可能会附有通俗易懂的语言摘要，以帮助对该领域有一定了解但不具备深入专业知识的读者了解重要的医学进展。

Pediatric Drugs创刊于1999年，由ADIS INT LTD出版商出版，收稿方向涵盖PEDIATRICS - PHARMACOLOGY & PHARMACY全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度>12周，或约稿，影响因子指数2.519，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。